NovoSeven (eptacog alfa (activated)) is a protein pharmaceutical. Eptacog alfa (activated) was first approved as NovoSeven on 1996-02-23. It has been approved in Europe to treat factor VII deficiency, hemophilia a, hemophilia b, and thrombasthenia.
|Common Name||Eptacog alfa (activated)|
|Indication||factor vii deficiency, hemophilia a, hemophilia b, thrombasthenia|